Diplomat Pharmacy (NYSE:DPLO) Releases FY19 Earnings Guidance

Diplomat Pharmacy (NYSE:DPLO) issued an update on its FY19 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of ($2.69-2.55) for the period, compared to the Thomson Reuters consensus estimate of ($0.54). The company issued revenue guidance of $4.7-5.0 billion, compared to the consensus revenue estimate of $4.91 billion.Diplomat Pharmacy also updated its FY 2019 guidance to $-2.69–2.55 EPS.

NYSE DPLO traded up $0.40 on Friday, reaching $5.72. The stock had a trading volume of 2,792,765 shares, compared to its average volume of 603,767. The firm has a 50 day simple moving average of $5.57. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.00 and a quick ratio of 0.66. Diplomat Pharmacy has a 1 year low of $4.17 and a 1 year high of $21.48. The company has a market capitalization of $382.53 million, a P/E ratio of 28.60 and a beta of 1.06.

Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Friday, August 9th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Diplomat Pharmacy had a negative net margin of 5.85% and a positive return on equity of 1.38%. The firm had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.23 billion. During the same quarter last year, the firm earned ($0.05) EPS. The business’s revenue for the quarter was down 9.1% compared to the same quarter last year. On average, research analysts forecast that Diplomat Pharmacy will post -0.55 EPS for the current year.

Several analysts have recently issued reports on DPLO shares. Zacks Investment Research downgraded Diplomat Pharmacy from a buy rating to a hold rating in a research note on Tuesday, July 16th. Credit Suisse Group decreased their price target on Diplomat Pharmacy from $8.00 to $6.00 and set a neutral rating for the company in a research note on Monday, April 29th. ValuEngine upgraded Diplomat Pharmacy from a buy rating to a strong-buy rating in a research note on Thursday, August 1st. Finally, Guggenheim started coverage on Diplomat Pharmacy in a research note on Wednesday, April 17th. They set a neutral rating and a $6.00 price target for the company. Two analysts have rated the stock with a sell rating, ten have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $9.96.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Featured Story: Price-Sales Ratio

Earnings History and Estimates for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.